SHEPLER ROBERT G 4

4 · Akoya Biosciences, Inc. · Filed Jul 10, 2025

Form 4

Period: 2025-07-08

Director

Transactions

Other
Stock Option (right to buy)
2025-07-08−30,549→ 0 total
Exercise: $11.24Exp: 2032-06-01→ Common Stock (30,549 underlying)
Other
Stock Option (right to buy)
2025-07-08−56,322→ 0 total
Exercise: $5.70Exp: 2033-06-01→ Common Stock (56,322 underlying)
Other
Stock Option (right to buy)
2025-07-08−50,000→ 0 total
Exercise: $2.01Exp: 2034-06-01→ Common Stock (50,000 underlying)
Other
Stock Option (Right to Buy)
2025-07-08−16,860→ 0 total
Exercise: $21.95Exp: 2031-05-21→ Common Stock (16,860 underlying)

Footnotes (2)

[F1]Disposition of shares pursuant to that certain Amended and Restated Agreement and Plan of Merger dated as of April 28, 2025, as amended (the "Merger Agreement"), by and among Quanterix Corporation, a Delaware corporation ("Quanterix"), Wellfleet Merger Sub, Inc., a Delaware corporation and wholly owned subsidiary of Quanterix ("Merger Sub"), and Issuer. On July 8, 2025 (the "Closing Date"), Merger Sub merged with and into Issuer (the "Merger"), with Issuer surviving the Merger as a wholly owned subsidiary of Quanterix.
[F2]Pursuant to the Merger Agreement, as of the Closing Date, each outstanding option to purchase Issuer common stock was accelerated and each option with a per share exercise price equal to or greater than the Per Share Merger Consideration (as defined in the Merger Agreement) was automatically terminated and cancelled for no consideration.

Documents

1 file